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There is much interest in developing stem cells and the cells derived from them as 
therapies for treating human disease and injury, but many biological, technological and 
regulatory hurdles have to be overcome before these cell therapies can be brought to 
commercial fruition. Not a day goes by without news of 
another advance in steering stem 
cells, and the cells derived from 
them, toward therapies for treating 
human disorders. For example, last 
month StemCells, Inc., a Palo Alto 
biotechnology firm, announced that 
it has joined forces with clinicians 
at Oregon Health and Science Uni-
versity for an FDA-approved Phase 
I clinical trial to transplant neural 
stem cells purified from human fetal 
brain tissue into the brains of infants 
with Batten’s disease. The hope is 
that the transplanted cells will pro-
duce the lysosomal enzyme that is 
missing in this fatal disease. “We’re 
all looking for a sound success 
where the delivery of cells makes a 
difference. It would be enormously 
encouraging,” says George Daley, 
a stem cell researcher at Harvard 
Medical School.
The overall vision for cell-based 
therapies, also called regenerative 
medicine, seems deceptively simple: 
Use healthy living cells to replace dis-
eased, dying, or missing cells or tis-
sues. One approach is to obtain suf-
ficient numbers of a specific cell type 
derived from fetal or adult human 
stem cells, or from human embry-
onic stem cells, and then transplant 
an appropriate “dose” of these cells 
into the patient’s body in the correct 
location. As researchers are discov-
ering, however, turning living cells 
into transplantable therapies is a 
complex multistep process.
The FDA’s Center for Biologics 
Evaluation and Research (CBER) is 
responsible for overseeing thera-
peutics composed of human cells, 
tissues, and cellular and tissue-based products—or HCT/Ps. So 
far only one product, Carticel, has 
been licensed, which industry ana-
lysts say clearly indicates just how 
young the regenerative medicine 
field actually is and how many chal-
lenges it faces. Carticel, manufac-
tured by Genzyme, is an autologous 
cell therapy for repairing injured 
knee cartilage. It was approved 
by the FDA in 1997 and passed its 
10,000th patient milestone in 2004. 
Chondrocytes from the patient’s 
healthy cartilage are obtained by 
biopsy and cultured in the labora-
tory to expand the cell population, 
which is then implanted into the 
patient’s injured knee. Several tis-
sue-engineered products, primarily 
for skin repair, have been approved 
by another section of the FDA, the 
Center for Devices and Radiologi-
cal Health. Because engineered 
products often combine a biological 
product with a medical device, from 
a regulation point of view, they are 
considered separately from prod-
ucts composed purely of cells.
Fashioning a cell therapy that 
works effectively in the body may 
require more R&D than is required for 
making drugs. “Since these products 
contain living cells, a number of fac-
tors contribute to the challenges of 
manufacturing and [FDA] approval,” 
noted FDA public affairs specialist 
Paul Richards in an email, “including 
the potential for adventitious agent 
contamination, the need for aseptic 
processing, the inability to ‘sterilize’ 
the final product and assurance they 
are free from infectious diseases.” 
Distribution of these products can 
also be a challenge, says Richards, Cell due to their short shelf life and the 
need to ensure that they remain 
genetically stable, that is, that they 
do not acquire mutations.
That there is only one FDA-
approved cell product on the market 
does not reflect the actual number 
of cell therapies available because 
approval is not required for cell thera-
pies “that are minimally manipulated, 
labeled or advertised for homologous 
use only, and not combined with a 
drug or device,” according to FDA 
specifications. A surgeon who takes 
bone marrow cells from a patient’s 
hip bone and immediately puts them 
back into the same patient’s blood-
stream does not have to pause for a 
multi-year review process. However, 
if cells, whether autologous (from the 
patient) or allogeneic (from a donor), 
are cultured for twenty-four hours or 
longer—that is, manipulated—then 
FDA oversight is required. (Oversight 
of bone marrow transplantation, 
as well as whole organ transplants, 
falls under the purview of the Health 
Resources Services Administration 
and not the FDA.)
For the many cell therapies cur-
rently in the R&D pipeline that are 
more than minimally manipulated, 
their developers must overcome 
numerous manufacturing hurdles if 
their product is to pass FDA muster. 
Simply knowing which type of cell 
will work best for treating a particu-
lar disorder can take several years 
to test. For instance, there are as 
many as twelve different types of 
cells under investigation for treating 
cardiovascular disease, according 
to Robert Deans, vice president of 
regenerative medicine at Athersys, 125, April 7, 2006 ©2006 Elsevier Inc. 
Inc., a Cleveland-based biotech 
company. They range from stem and 
progenitor cells derived from umbili-
cal cord blood, bone marrow, blood 
vessels, adipose tissue, and the heart 
itself to human embryonic stem cells 
that have the potential to generate 
the appropriate cell type. Athersys, 
together with physicians from the 
Cleveland Clinic, has its sights set on 
using a mesenchymal stem cell from 
adult bone marrow (first identified by 
Catherine Verfaillie in 1999) to treat 
acute myocardial infarction. The bio-
tech company expects to soon file an 
IND (investigational new drug appli-
cation) with the FDA for their prod-
uct “MultiStem,” the first step on the 
path to a Phase I clinical trial.
The technology of cell selection—
the ability to isolate the exact type of 
cell needed in sufficient quantities for 
an effective dose—has proved prob-
lematic for potential cell therapies. 
Flow cytometry accurately sorts 
cells into different populations but 
is slow and uses an aerosol phase 
that could expose cells to contami-
nants in the air. “Every mouse paper 
you read probably has used an opti-
cal cell sorter, because that’s the 
most precise way of selecting cells,” 
observes John Gilbert, CEO of Cyto-
nome, a Boston company that is 
designing an optical sorter with no 
aerosol phase. “But if you want to 
move to humans, you’ve got a prob-
lem—safety and speed.” Although 
Cytonome is “still in stealth mode,” 
Gilbert says his company’s machine 
“is an optical sorter that has no aero-
sol phase—its fluidics are in a closed 
disposable cartridge—and it’s fast 
enough to make a human cell dose.”
The next challenge is how to 
deliver cell therapies to the patient. 
For example, should cell therapies 
for repair of heart tissue be routed 
through the arteries or veins, or 
injected straight into heart tissue? 
Keith March at the Indiana Univer-
sity School of Medicine, who studies 
cardiovascular repair in a pig animal 
model, says “We have found that 
delivery devices and methods vary 
greatly in their ability to disperse 
cells in the heart, as well as in the 
efficiency and consistency of cell 10 Cell 125, April 7, 2006 ©2006 Elsevieplacement. It is therefore critical to 
understand and refine delivery tech-
niques as one is developing thera-
peutic cells.”
Magnetic resonance imaging 
(MRI) is now being applied to track 
the delivery of magnetically labeled 
cells after transplant to ensure that 
they reach their destination and do 
not wander into surrounding tis-
sues. For example, a recent Nature 
Biotechnology paper reported mag-
netic resonance tracking of a den-
dritic cell vaccine injected into the 
lymph nodes of eight patients with 
melanoma. The autologous dendritic 
cells derived from the patient were 
loaded with tumor antigen and iron 
oxide particles in the laboratory prior 
to injection. MRI revealed that in four 
patients, the dendritic cells ended 
up not in the lymph nodes but in the 
surrounding fat, which may explain 
the limited effect of dendritic cell 
vaccines in clinical trials. The Neth-
erlands, China, and other countries 
have already adopted magnetic 
resonance tracking in patients. How-
ever, it may be one to three more 
years before the FDA approves an 
IND application for magnetic reso-
nance tracking in the United States, 
says Joseph Frank, chief of the NIH’s 
Experimental Neuroimaging Section 
and a pioneer of the technology.
Even when the biological and 
technical hurdles are overcome, 
there is still the regulatory gauntlet 
to get through. Since 1993, the FDA 
has been modernizing its regulations 
to keep up with the research com-
munity’s growing interest in treating 
patients with cell- and tissue-based 
products. Addressing the FDA’s 
concerns regarding the develop-
ment of stem cell-based products, 
Darin Weber, former chief of the 
FDA’s cell therapies branch and cur-
rently with The Biologics Consulting 
Group, advises “You want to know 
your product better than anyone in 
the world.” A thorough understand-
ing of what your cells do in a dish, an 
animal, and a human will help answer 
the questions the FDA is inevitably 
going to ask you about your product, 
questions like: Where, specifically, 
will the cells be placed, and if they r Inc.migrate, where will they go? How well 
do they integrate into the host, and 
what is the extent of their functional 
activity? Safety studies, says Weber, 
should address dosing issues, deliv-
ery techniques, immunosuppression 
regimens, and potential serious side 
effects, including the cells’ potential 
to form tumors.
Whether researchers are or aren’t 
manipulating cells, they should 
be attentive to three new key FDA 
rules. These additions are intended 
to strengthen the FDA’s monitor-
ing of cells and tissues destined for 
therapeutic application “while mini-
mizing regulatory burden,” accord-
ing to CBER. The first rule, which 
became fully effective in January ’04, 
requires any establishment that uses 
HCT/Ps to register with the FDA and 
list their manufactured products. The 
second, “donor eligibility,” helps to 
ensure that tissues meant for trans-
plant come from individuals who are 
free of disease, with an emphasis on 
communicable diseases. The third 
rule—which, along with the “donor 
eligibility” rule, took effect in May last 
year—underscores good tissue prac-
tice (GTP) and requires research-
ers to follow specific measures that 
guard against tissue contamination.
“Stem-cell based therapies pro-
vide regulatory challenges due to 
their intrinsic biologic properties, 
namely, their robust capacity for 
self-renewal and replication and their 
ability to differentiate into a variety 
of tissue types,” said Chris Midden-
dorf, Chief of the FDA’s Consumer 
Affairs Branch, in an email. Thus, 
although preclinical proof-of-con-
cept and toxicological assessment 
testing for cell-based therapies has 
much in common with testing for 
drug approval, “the type and extent 
of preclinical testing expected may 
vary depending on perceived risks 
to the patient posed by the funda-
mental biology of a cellular therapy, 
including stem cells…. It is FDA’s 
intention that the extent of regulatory 
oversight be commensurate with the 
potential risk posed by the product.”
When it comes to approaching 
the FDA for INDs for cell therapies, 
the action is principally at the level 
of small and medium-sized biotech 
companies, with much less par-
ticipation by big pharma. This is 
not altogether surprising, suggests 
Peter Mountford, CEO of Stem Cell 
Sciences—a twelve-year-old bio-
tech company that aims to gener-
ate neural cell types from human 
embryonic stem cells to treat Par-
kinson’s disease and other disor-
ders. “Really, biotech needs to be 
coordinating this project,” of grow-
ing cells and scaling up their num-
bers for therapies, says Mountford. 
“Big pharma isn’t going to do it, 
because they are small molecule 
companies, and that’s their focus. 
And it’s also ethically very sensitive 
for them—they are very concerned 
about public reactions. If a large 
pharma was to announce that they 
had entered the embryonic stem 
cell field, it could knock one percent 
off their market capitalization; that’s 
a very expensive announcement. 
So it’s not for the pharmaceutical 
industry—although they will buy into 
the business opportunity when it’s 
more mature. It’s truly a biotech-
based initiative.”
“By and large, big pharma is built 
on pills and injectibles, and hasn’t 
liked the stem cell model,” points 
out Steven Burrill, CEO of San Fran-
cisco-based Burrill and Company, a 
life sciences firm with ties to venture 
capital and merchant banking. Burrill 
foresees a time, nevertheless, when 
cell therapies will “be an exciting and 
explosive part of the medical indus-
try,” drawing the keen interest of both 
venture capital and major pharma-
ceutical companies. Within ten years, 
he estimates, such interest will begin 
“perking up,” as more and more cell 
therapies prove themselves.
Even though the majority of cell 
therapies are being created in the 
academic setting, in Mountford’s 
view, academic researchers shouldn’t necessarily coordinate the scaling 
up of cell therapies as their place is 
at the cutting edge of basic research. 
A current conundrum, notes Darin 
Weber, is to what extent scientific 
results from academic labs can be 
translated into commercial products. 
Even if they spin off into biotech ven-
tures, they may not be commercially 
lucrative enough to turn the heads of 
big pharma. There are, nonetheless, 
“many companies in the traditional 
pharmaceuticals—both drug and 
medical devices—who are investing 
cautiously in small biotech behind 
the scenes, hoping that a few actu-
ally come to fruition,” says Weber.
To date little venture capital has 
flowed into the stem cell therapeu-
tics field. In Peter Mountford’s opin-
ion, venture capitalists tend to have 
the misconception that stem cell 
therapy is as risky as gene therapy, 
which investors shied away from 
after the death of a patient in 1999. 
“Gene therapy,” observes Mountford 
“was a whole new concept that was 
developed to do something that has 
no real precedent in normal biology”: 
using viruses to deliver genes into 
cells. Cell-based therapy is differ-
ent as it “reproduces what the body 
does normally.”
Pfizer, a pharma giant that “is 
committed to small molecules and 
not developing any cell-based thera-
pies,” says John Hambor with Pfizer 
Global Research and Development, 
has been studying mouse embryonic 
stem cells for more than fifteen years 
for other reasons. Inducing these 
cells to differentiate into dopamin-
ergic, serotonergic, or other types 
of neurons could provide a renew-
able source of nerve cells for test-
ing new small-molecule drugs for 
treating neurological diseases such 
as Parkinson’s and schizophrenia. 
Some onlookers believe that using 
stem cells for testing new drugs Cell has the potential to wind up a big-
ger business than using stem cells 
as therapies. “Stem cells represent 
an important new source of assays 
for drug development,” observes 
George Daley, “and in the near term 
are likely to prove more valuable as 
tools for drug research rather than 
therapeutic entities themselves. Until 
cells can be mass produced as read-
ily and cheaply as small molecules, 
and used off-the-shelf without hav-
ing to be customized to individual 
patients, big pharma will continue to 
focus on what it does best, making 
small molecule drugs.”
Pharmaceutical companies, mean-
while, are expected to keep adding to 
an expanding group of manufactured 
drugs that beneficially trigger the 
proliferation of stem and progenitor 
cells in the body. This “endogenous” 
approach, exemplified by the growth 
factors erythropoietin and throm-
bopoietin (which stimulate produc-
tion of red blood cells and platelets, 
respectively), handily avoids all of 
the difficulties associated with trans-
planting cells. But activating cells 
in the body to do medicine’s bid-
ding requires its own set of complex 
maneuvers.
Clearly, stem cells and the cells 
derived from them have great poten-
tial to serve medicine—from thera-
pies, to drug testing, to teaching us 
more about the body’s biology. With 
the cache of FDA-approved new 
drugs having fallen from over 50 in 
1996 to 20 in 2005, according to a 
New York Times report, the vision 
of what cell-based medicines might 
achieve has injected optimism into 
the difficult search for new ways to 
treat human disease.
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